UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 86

Sortiert nach

Guidelines of care for the management of psoriasis and psoriatic arthritis

Journal of the American Academy of Dermatology, 2011-07, Vol.65 (1), p.137-174

2011

Link zum Volltext

Verfügbarkeit prüfen

Research gaps in psoriasis: Opportunities for future studies

Journal of the American Academy of Dermatology, 2014-01, Vol.70 (1), p.146-167

2014

Link zum Volltext

Verfügbarkeit prüfen

Clinical Goals and Barriers to Effective Psoriasis Care

Dermatology and therapy, 2019-03, Vol.9 (1), p.5-18

2019

Link zum Volltext

Verfügbarkeit prüfen

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Journal of the American Academy of Dermatology, 2018-08, Vol.79 (2), p.302-314.e6

2018

Link zum Volltext

Verfügbarkeit prüfen

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

Journal of the American Academy of Dermatology, 2019-04, Vol.80 (4), p.1073-1113

2019

Link zum Volltext

Verfügbarkeit prüfen

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Journal of the American Academy of Dermatology, 2011-07, Vol.65 (1), p.137-174

2011

Link zum Volltext

Verfügbarkeit prüfen

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4S), p.S74

Leonardi, Craig L

2016

Link zum Volltext

Verfügbarkeit prüfen

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis : Overview and guidelines of care for treatment with an emphasis on the biologics

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.851-864

2008

Link zum Volltext

Verfügbarkeit prüfen

Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Journal of the American Academy of Dermatology, 2020-02, Vol.82 (2), p.519-522

2020

Link zum Volltext

Verfügbarkeit prüfen

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Journal of the American Academy of Dermatology, 2021-02, Vol.84 (2), p.398-407

2021

Link zum Volltext

Verfügbarkeit prüfen

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2021-03, Vol.35 (2), p.229-238

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis

American journal of clinical dermatology, 2018-06, Vol.19 (3), p.437-447

2018

Link zum Volltext

Verfügbarkeit prüfen

A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists

Diagnostic pathology, 2008-03, Vol.3 (1), p.13-13, Article 13

2008

Link zum Volltext

Verfügbarkeit prüfen

Highlights of Skin Disease Education Foundation's 41st Annual Hawaii Dermatology Seminar

Seminars in cutaneous medicine and surgery, 2017-06, Vol.36 (4S), p.S52-S59

2017

Link zum Volltext

Verfügbarkeit prüfen

Guidelines of care for the management of psoriasis and psoriatic arthritis

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.826-850

2008

Link zum Volltext

Verfügbarkeit prüfen

Guidelines of care for the management of psoriasis and psoriatic arthritis

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.851-864

2008

Link zum Volltext

Verfügbarkeit prüfen

Ten Years On

Dermatologic clinics, 2015, Vol.33 (1), p.111-125

2015

Link zum Volltext

Verfügbarkeit prüfen

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by

The Journal of clinical and aesthetic dermatology, 2016-09, Vol.9 (9 Suppl 1), p.S5-S29

2016

Link zum Volltext

Verfügbarkeit prüfen

13883 Maintenance of response through 136 weeks of long-term continuous risankizumab treatment: An analysis of patients from UltIMMa-1 and UltIMMa-2

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB14-AB14

2020

Link zum Volltext

Verfügbarkeit prüfen

Small Molecules for Psoriasis

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4S), p.S65

Leonardi, Craig L

2016

Link zum Volltext

Verfügbarkeit prüfen

Identifying and Managing Complications and Comorbidities in Patients With Psoriasis

Seminars in cutaneous medicine and surgery, 2015-03, Vol.34 (2 Suppl), p.S30-S33

Duffin, Md Ms, Kristina Callis

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

The Lancet (British edition), 2013-08, Vol.382 (9894), p.780-789

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 86

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis:Master (3349 titles)

ThemaPsoriasis - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(65)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Guidelines of care for the management of psoriasis and psoriatic arthritis

Research gaps in psoriasis: Opportunities for future studies

Clinical Goals and Barriers to Effective Psoriasis Care

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis : Overview and guidelines of care for treatment with an emphasis on the biologics

Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis

A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists

Highlights of Skin Disease Education Foundation's 41st Annual Hawaii Dermatology Seminar

Guidelines of care for the management of psoriasis and psoriatic arthritis

Guidelines of care for the management of psoriasis and psoriatic arthritis

Ten Years On

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by

13883 Maintenance of response through 136 weeks of long-term continuous risankizumab treatment: An analysis of patients from UltIMMa-1 and UltIMMa-2

Small Molecules for Psoriasis

Identifying and Managing Complications and Comorbidities in Patients With Psoriasis

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Aktive Filter

Suchergebnisse filtern